Related Experiment Video
Updated: Mar 8, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.3K
Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale.
Michael Böhm1, Sebastian Ewen1, Felix Mahfoud1
1Departments of Internal Medicine III, Cardiology, Angiology, and Intensive Care, Saarland University Hospital, Homburg/Saar, Germany.
Korean Circulation Journal
|February 4, 2017
Summary
Renal denervation may treat heart failure by reducing sympathetic nervous system activity. Further research is needed to prove its effectiveness in patients with heart failure and related conditions.
Area of Science:
- Cardiology
- Nephrology
- Neuroscience
Background:
- Sympathetic nervous system (SNS) overactivation is linked to heart failure hospitalizations and mortality.
- Renal denervation effectively reduces SNS activity in patients with resistant hypertension.
- Pilot studies are exploring renal denervation for heart failure treatment.
Purpose of the Study:
- To explore the pathophysiological basis for using renal denervation in heart failure.
- To assess the impact of renal denervation on heart failure surrogates.
- To investigate renal denervation as a potential treatment for heart failure comorbidities.
Main Methods:
- Review of pathophysiological mechanisms linking SNS to heart failure.
- Analysis of data from pilot trials on renal denervation in heart failure.
- Evaluation of renal denervation's effect on heart failure biomarkers and clinical outcomes.
Main Results:
- The SNS plays a significant role in the pathophysiology of heart failure.
- Renal denervation demonstrates potential in modulating SNS activity relevant to heart failure.
- Comorbidities like sleep apnea and arrhythmias, mediated by SNS, may also benefit.
Conclusions:
- Renal denervation presents a promising, yet unproven, therapeutic strategy for heart failure.
- Targeting SNS overactivity via renal denervation warrants further clinical investigation.
- The approach may offer benefits for heart failure and its associated conditions.
More Related Videos
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
818
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
24.5K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:30Heart Failure V: Medical Management
443
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
443
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K